Article

Gabapentin and Risk of Pancreatic Cancer and Renal Cancer

The focus of this clinical trial was evaluate how exposure to gabapentin increased a patient's risk of developing pancreatic or renal cancers.

Study Type: Observational

Age/Gender Requirements: Not listed

Sponsor: GlaxoSmithKline

Purpose: The main objective of this clinical trial was "to determine whether exposure to gabapentin is associated with an increased risk of dveloping pancreatic cancer or renal cancer in the United Kingdom (UK) General Practice Research Database (GPRD)."

ClinicalTrials.gove identifier: NCT01138124

Click here to access additional information about the clinical trial.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
4 experts are featured in this series.
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.